product summary
Loading...
company name :
R&D Systems
product type :
other
product name :
Human Vanilloid R1/TRPV1 (AAM89472) VersaClone cDNA
catalog :
RDC2866
quantity :
10 ug
price :
643 USD
more info or order :
image
image 1 :

product information
master code :
RDC2866
SKU :
RDC2866
product name :
Human Vanilloid R1/TRPV1 (AAM89472) VersaClone cDNA
unit size :
10 ug
description :
R&D Systems Human Vanilloid R1/TRPV1 (AAM89472) VersaClone cDNA clone contains the complete ORF for Vanilloid R1/TRPV1, along with a Kozak consensus sequence for optimal translation initiation. The gene insert is flanked with convenient multiple cloning sites which can be used to easily cut and transfer the gene cassette into your desired expression vector. The Vanilloid R1/TRPV1 insert is sequence verified and the entire plasmid DNA and insert translated sequences are provided.
target :
Vanilloid R1/TRPV1
category :
cDNA Clones
species :
Human
accessionNumbers :
AAM89472
USD :
643 USD
alt names :
Capsaicin receptor, Osm-9-like TRP channel 1, OTRPC1, transient receptor potential cation channel subfamily V member 1, transient receptor potential cation channel, subfamily V, member 1, transient receptor potential vanilloid 1a, transient receptor potential vanilloid 1b, TRPV1, Vanilloid receptor 1, vanilloid receptor subtype 1, VanilloidR1, VR1, VR1DKFZp434K0220
storage :
Store the unopened product at -20 to -70 ░C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments